| DB ID | MyCo_3049 |
| Title | β-D-glucan surveillance with preemptive anidulafungin for invasive candidiasis in intensive care unit patients: a randomized pilot study |
| Year | 2012 |
| PMID | 22879929 |
| Fungal Diseases involved | Invasive candidiasis |
| Associated Medical Condition | ICU Patients |
| Genus | Candida |
| Species | spp. |
| Organism | Candida spp. |
| Ethical Statement | The study protocol was approved by the Duke University Institutional Review Board (University of Utah, Salt Lake City, Utah, United States of America). |
| Site of Infection | None |
| Opportunistic invasive | Invasive |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | BDG |
| Biomarker Full Name | 1-3-beta-D-Glucan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | USA |
| Cohort | Between June 2008 and January 2011, adult patients (≥18 years) admitted to the Surgical ICUs for at least 3 days, who were also expected to require $2 additional days of intensive care, were screened. Sixty-four subjects were enrolled, with 1 proven and 5 probable cases of IC identified over a 2.5 year period. |
| Cohort No. | 64 |
| Age Group | 19–82 |
| P Value | p<0.001 |
| Sensitivity | 1 |
| Specificity | 0.75 |
| Positive Predictive Value | 0.3 |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Invasive candidiasis (IC) is associated with high mortality, prolonged hospitalization and excess costs. The majority of these infections are nosocomially acquired and frequently complicate the management of intensive care unit (ICU) patients. Most invasive Candida infections are due to C. albicans followed in frequency by C. glabrata, a species that is often fluconazole resistant, and other non-albicans Candida species. Antifungal prophylaxis reduces the overall incidence and associated mortality of IC, but a cost-effective approach requires targeting patients with the highest-risk of disease. |
| Technique | ELISA |
| Analysis Method | FDA approved Fungitell assay |
| ELISA kits | None |
| Assay Data | FDA- Fungitell®, Cape Cod International, Inc.; Falmounth, MA, USA |
| Validation Techniques used | FDA approved Fungitell assay |
| Up Regulation Down Regulation | Increase |
| Sequence Data | None |
| External Link | None |
